Isolates (79 in total) of Clostridium difficile obtained over a 2 year period from 785 patients suspected of having C. difficile-associated diarrhoea (CDAD) and being hospitalized in the University Hospital in Warsaw were characterized by toxigenicity profile and PCR ribotyping. Furthermore, their susceptibility to clindamycin and erythromycin was determined. ) to clindamycin and erythromycin was found in 39 (49 %) of the C. difficile isolates. Interestingly, 34 (94 %) of macrolide-lincosamide-streptogramin B (MLS B ) type resistance strains did not produce toxin A, but produced toxin B and were A " B + ribotype 017. Thirty-seven of the high-level resistance strains harboured the erythromycin-resistance methylase gene (ermB). C. difficile isolates (2/29) that had high-level clindamycin and erythromycin resistance, and belonged to PCR ribotype 046, were ermB negative. These investigations revealed that the predominant C. difficile strain isolated from symptomatic patients hospitalized in University Hospital in Warsaw was MLS B -positive clindamycin/erythromycin-resistant PCR ribotype 017.
Isolates (79 in total) of Clostridium difficile obtained over a 2 year period from 785 patients suspected of having C. difficile-associated diarrhoea (CDAD) and being hospitalized in the University Hospital in Warsaw were characterized by toxigenicity profile and PCR ribotyping. Furthermore, their susceptibility to clindamycin and erythromycin was determined. 
INTRODUCTION
Clostridium difficile is the main aetiological agent of antibiotic-associated diarrhoea, antibiotic-associated colitis and pseudomembranous colitis. The pathogenicity of this bacterium is determined by the production of two major toxins: enterotoxin A (TcdA) (A) and cytotoxin (TcdB) (B) (Borriello, 1998) . However, C. difficile strains producing only toxin B (A 2 B + ) can be isolated from cases of C. difficile-associated diarrhoea (CDAD) throughout the world Pituch et al., 2001 Pituch et al., , 2003 Kuijper et al., 2001; Alfa et al., 2000; Barbut et al., 2002; Johnson et al., 2003) .
The application of different typing methods has revealed that C. difficile is a heterogeneous species. Workers at the Anaerobe Reference Laboratory (ARL) in Cardiff developed a modification of the PCR-ribotyping method, based on the polymorphism in the 16S-23S rDNA intergenic region spacer, for the routine typing of C. difficile (O'Neill et al., 1996) . Every bacterial strain contains several rRNA operons, and there is a strain-dependent variation in the size and number of the 16S-23S intergenic spacer regions. Macrolide-lincosamide-streptogramin B (MLS B )-resistant C. difficile strains have been demonstrated to be the cause of epidemics of CDAD in different countries (Johnson et al., 1999; Kuijper et al., 2001; Pituch et al., 2003) . High-level resistance to clindamycin and erythromycin in C. difficile is encoded by the ermB gene (the erythromycin ribosomal methylase gene B), and this determinant is located on a conjugative transposon called Tn5398 (Wust & Hardegger, 1993; Mullany et al., 1995; Farrow et al., 2001) . The ermB MLS B -resistance determinant from C. difficile 630 contains two copies of an erm (B) gene (Farrow et al., 2000) . Spigaglia & Mastrantonio (2004) described five phenotypic classes (EC-a to EC-e), with characteristic susceptibility/resistance patterns to erythromycin and clindamycin, among the C. difficile strains.
The aim of this study was to determine the distribution of PCR ribotypes of C. difficile circulating in the University Hospital in Warsaw, Poland and to establish the relationship with MLS B -type resistance.
METHODS
C. difficile isolates. A total of 785 liquid stool samples was collected from patients for whom clinicians specifically requested investigations for C. difficile toxin, between January 2002 and December 2003. The samples originated from patients hospitalized in different wards of University Hospital in Warsaw. From these faecal samples, 79 C. difficile isolates were obtained from different wards: transplant (n=36), surgery (n=16), internal medicine (n=16), orthopaedics (n=6), intensive care (n=2), dermatology (n=1), gynaecology (n=1), urology (n=1). Three reference strains were included in this study as controls, namely, toxigenic C. difficile
) and A 2 B + C. difficile GAI 95 601, isolated by H. Kato (Institute of Anaerobic Bacteriology, Gifu University School of Medicine, Gifu, Japan), were used as an internal control for detecting repeating sequences in the tcdA gene.
Culture and identification of C. difficile isolates. Isolation of C. difficile was performed on selective Columbia Agar supplemented with cycloserine-cefoxitin and amphotericin B (CCCA medium; bioMerieux), as described previously (Pituch et al., 2001 ). Plates were incubated in an anaerobic chamber (Forma Scientific) at 37 uC for 4 days. The isolates were identified as C. difficile by the characteristic morphology of the colonies and horse odour, green-yellow fluorescence under UV light (365 nm), Gram staining and the API 20A biochemical test (bioMérieux).
Toxin detection. A single colony was transferred into brain heart infusion broth (BHI) (Difco) and grown for 48 h. Supernatants were collected by centrifugation at 3000 g for 15 min. TcdA was detected by an immunochromatography assay using anti-toxin A antibody labelled with latex: the C. difficile toxin A test (Oxoid). Additionally, the immunoenzymic assay C. difficile TOX A/B test (TechLab) was used for detection of either TcdA or TcdB toxins, or both. The procedures were carried out according to the manufacturer's instructions. TcdB was detected by a cytotoxicity assay on the McCoy cell line. Tenfold serial dilutions of culture filtrate were added in duplicate to McCoy cells and incubated for 24 h. C. difficile strain VPI 10463 was used as a positive control. The cytopathic effect (CPE) was observed by inverse microscopy. If this CPE could be neutralized by polyclonal antiserum to C. difficile (C. difficile TOX-B Test; TechLab), the test was considered positive.
PCR assays for detection of tcdA and tcdB genes. Crude template DNA was prepared using genomic DNA PREP-PLUS (A & A Biotechnology) according to the manufacturer's instructions. A 630 bp fragment of the tcdA gene and 399 bp fragment of tcdB gene were amplified using specific primer pairs YT28-YT29 and YT17-YT18, respectively, as described previously (Pituch et al., 2003) . The cycling conditions for both PCRs were: one predenaturation cycle at 94 uC for 45 s, and 55 uC for 30 s and 70 uC for 45 s, for 35 cycles, as described previously. Deletion in repeating regions of the tcdA gene was detected with the NK9-NKV011 primer pairs, as described previously (Kato et al., 1999) . The PCR cycling conditions were 95 uC for 20 s, 60 uC for 2 min for 40 cycles.
PCR assay for detection of binary-toxin genes (cdtA and cdtB). Primers described by Stubbs et al. (1999) were used for amplification of the binary-toxin genes cdtA and cdtB, as described previously (Pituch et al., 2005) .
PCR ribotyping. All isolates were typed by the PCR-ribotyping method described by O'Neill et al. (1996) and Stubbs et al. (1999) . The oligonucleotide primers used were P3 (59-CTG GGG TGA AGT CGT AAC AAG G-39) and P4 (59-GCG CCC TTT GTA GCT TGA CC-39). Banding patterns were compared with those of the library of PCR ribotypes at the ARL, Cardiff.
Determination of antibiotic susceptibility and ermB gene PCR. MICs of clindamycin and erythromycin were determined by E-test (AB Biodisc) according to the manufacturer's instructions. Cultures were adjusted to an OD 950 1 (using a bioMérieux ATB 1550) on the McFarland scale and were streaked to confluence on the surface of Brucella agar plates. Plastic strips with antibiotics were applied and the plates were incubated anaerobically at 37 uC for 48 h. The MIC was measured at the intercept of the inhibition ellipses. According to NCCLS (National Committee for Clinical Laboratory Standards) recommendations, resistance was defined as follows: ¢8 mg clindamycin l 21 and ¢8 mg erythromycin l
21
. A 688 bp fragment of ermB was amplified using specific primer pairs 2980 (59-AAT AAG TAA ACA GGT AAC GTT-39) and 2981 (59-GCT CCT TGG AAG C TG TCA GTA G-39) (Johnson et al., 1999) . The PCR cycling conditions included 30 cycles of 60 s at 95 uC, 120 s at 55 uC and 180 s at 72 uC.
RESULTS

Toxigenicity of clinical isolates
During the study period, a total of 785 stool samples was investigated for C. difficile. All of these faecal samples were from symptomatic adults hospitalized in different units of the University Hospital in Warsaw. The overall incidence of toxin-positive C. difficile-positive symptomatic patients among those with suspected CDAD was 66 % (526), with individual incidence in the units as follows: transplant 64 % (156), surgery 23 % (22) and internal medicine 57 % (72). From toxin-positive patients, 79 C. difficile isolates were obtained: 36 from transplant patients, 16 from patients hospitalized in the internal medicine unit, 16 from patients hospitalized in the surgery unit, 6 from orthopaedic patients, 2 from patients hospitalized in the intensive care unit, 1 from a urology patient, 1 from a gynaecology patient and 1 from a patient hospitalized in the dermatology unit. Three phenotypic classes of patterns of susceptibility/ resistance to erythromycin/clindamycin were identified in all strains studied (Table 2 ). In our laboratory, the EC-a class was characterized by susceptibility to both erythromycin (MIC range 0?023-1?5 mg l ) strains two classes of patterns of susceptibility/resistance to erythromycin and clindamycin were observed. Six non-toxigenic isolates were EC-a and one was EC-b.
Of the C. difficile isolates of class EC-a, all were ermB negative. Out of the 37 strains showing the EC-b phenotype, 35 harboured the ermB gene, but 2 strains did not. All four C. difficile strains of class EC-f were ermB gene negative.
DISCUSSION
The present study describes a comparative analysis of C. (Pituch et al., 2003) .
The data generated from the present study showed that all 79 C. difficile strains isolated from patients with antibioticassociated diarrhoea were typable by the PCR-ribotyping method. Interestingly, the 35 C. difficile-positive patients harboured 15 highly diverse PCR ribotypes of A + B + strains.
Two distinct toxigenic (A + B + ) clones were found to circulate our hospital (PCR ribotypes 014 and 046). Rotimi et al. (2003) described three different clones belonging to PCR ribotypes 097, 078 and 039, among isolates from patients in hospitals in Kuwait. The most predominant ribotype in a Hungarian survey was PCR ribotype 087 (A + B + ), which accounted for 39 % of all isolates (Urban et al., 2001) . In Warsaw, we did not observe these ribotypes that were present in Hungary and Kuwait. Among clinical strains isolated in the University Hospital in Warsaw only one isolate was found that belonged to ribotype 001, which is dominant in the United Kingdom (Pituch et al., 2003) . One C. difficile binary positive strain (no. 2145) belonged to ribotype 033. In our earlier study, the same isolate belonged to Polish ribotype D (Pituch et al., 2005) .
In our hospital we observed MLS B -type resistant variant toxin C. difficile strains that were responsible for many cases of CDAD. In our earlier study we found MLS B resistance among all analysed C. difficile A 2 B + strains and we concluded that C. difficile strains harbouring the ermB gene are significantly associated with CDAD (Pituch et al., 2001 (Pituch et al., , 2003 . Van den Berg et al. (2004) analysed 39 C. difficile strains that did not produce toxin A but produced toxin B (A 2 B + ), originating from Canada, the United States, Poland, the United Kingdom, France, Japan and The Netherlands. All Polish A 2 B + isolates, designated earlier as Polish ribotype A, belonged to ribotype 017. Clindamycin resistance encoded by the ermB gene was found in 33 of the 39 C. difficile strains. They concluded that clindamycinresistant C. difficile A 2 B + strains of PCR ribotype 017 have a clonal worldwide spread. MLS B -type resistance is frequently found in C. difficile strains that are resistant to other antibiotics (Ackermann et al., 2003; Barbut et al., 2002) . It is interesting because Delmee & Avesani (1988) did not find resistance to clindamycin in toxin variant C. difficile strains (A 2 B + ). Spigaglia & Mastrantonio (2004) performed a comparative analysis of C. difficile strains belonging to distinct genetic lineages, focusing on PaLoc (pathogenicity locus) analysis and antibiotic resistance. In this survey, five classes of patterns of susceptibility/resistance (EC-a to EC-e) to erythromycin and clindamycin were identified. Most of the recent isolates belonged to EC-d and EC-e classes, although erythromycin resistant in vitro, they did not harbour the ermB gene, and two strains of the EC-d class were resistant to clindamycin only after induction with a subinhibitory concentration of the antibiotic. In our study, the main phenotypic classes of patterns of susceptibility/resistance to erythromycin/clindamycin, for all Polish strains, were identified: EC-a, EC-b (described by Spigaglia & Mastrantonio, 2004 ) and a new class designated by us as EC-f. We did not observe classes EC-c, EC-d and EC-e in our collection. The analysis of the genetic background of the resistance to clindamycin and erythromycin using PCR, showed the presence of the erythromycin-resistance methylase gene (ermB) in 36 C. difficile strains belonging to the ECb 1 phenotypic subclass. Interestingly, two MLS B -resistant C. difficile strains belonging to PCR ribotype 046, from the ECb 2 phenotypic subclass, were ermB negative. Resistance in those strains could possibly be due to mutations within the target site in the 23S rRNA, or a new mechanism of high resistance. Spigaglia & Mastrantonio (2004) showed that the EC-b phenotypic class in their Italian collection was always associated with the presence of an ermB gene, but Ackermann et al. (2003) have described ermB-negative C. difficile strains with high level resistance to clindamycin and/ or erythromycin. Ackermann et al. (2003) suggest it is probable that other erm genes are responsible for this highlevel resistance to clindamycin and erythromycin.
In streptococci, as well as in many other Gram-positive bacteria, target-site modification is a common resistance mechanism (Weisblum, 1995) . Genes belonging to the ermAM (ermB) gene class, which was founded in Streptococcus pyogenes, are linked with MLS B resistance. In addition, Seppala et al. (1998) found in S. pyogenes a gene other than ermB that mediated MLS B resistance called ermTR.
In our collection of C. difficile strains, we identified phenotype EC-f by the decreased susceptibility to clindamycin (MIC 4 mg l
21
) and susceptibility to erythromycin (MIC range 0?5-0?75 mg l
), and they were always ermB-gene negative. Spigaglia & Mastrantonio (2004) described that only C. difficile strains with susceptibility or decreased susceptibility to clindamycin were ermB-negative. Effluxmediated resistance confers only a low-level resistance to antimicrobial agents. Interestingly, among C. difficile strains belonging to ribotype 017 we observed three type clindamycin/erythromycin resistance patterns: EC-a/ermB negative, EC-b 1 /ermB positive, EC-f/ermB negative. MLS B type resistance was always associated with the ermB gene. Clindamycin-resistant C. difficile strains were found to be responsible for a large outbreak of CDAD in four hospitals in the USA. High-level resistance to clindamycin (MIC¢256 mg l
) was present in all 85 epidemic-strain isolates, but in only 7 out of 46 non-epidemic strain isolates. The epidemic strains were also highly resistant to erythromycin (MIC¢256 mg l 21 ) (Johnson et al., 1999) . In summary, resistance against clindamycin and erythromycin among Polish A 2 B + (ribotype 017) C. difficile strains was very frequent (94 %), but among A + B + and A 2 B 2 strains it was very rare (11 and 3 %, respectively). However, clindamycin resistance among C. difficile strain isolates is not new (Gerding & Johnson, 2001) , but further work is needed to elucidate the association of MLS B resistance with epidemic-spreading toxin variant C. difficile strains. Table 2 . Summary of phenotypic classes identified in 79 Polish C. difficile strains analysed for erythromycin and clindamycin susceptibility (Spigaglia & Mastrantonio, 2004 
